Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Clinical and Molecular Comparative Analysis of KRAS Exon 2 and KRAS Non-Exon 2 Mutated Colorectal Cancer.

Cancers·2026

Same author

Immune Checkpoint Inhibitor Outcomes Across Child-Pugh A, B, and C Hepatocellular Carcinoma: A Real-World Integrated Health-System Cohort.

Cancer treatment and research communications·2026

Same author

EMPIRE (NSABP FC-13): a biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable colorectal cancer with ctDNA-defined minimal residual disease.

Future oncology (London, England)·2026

Same author

A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma.

Journal of hepatology·2026

Same author

Targeting colorectal cancer stem-like cells: Overcoming therapeutic resistance and reprogramming the immunosuppressive niche.

Cancer letters·2026

Same author

Niraparib in pancreatic cancer with germline or somatic DNA damage repair (DDR) gene alterations (BRCA and beyond): A phase II study (NIRA-PANC).

The oncologist·2026

Search research articles

Related Experiment Video

Updated: May 28, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Adoptive T Cell Therapy Targeting MAGE-A4.

Kapil Chandora¹, Akshay Chandora¹, Anwaar Saeed²

¹Morehouse School of Medicine, 720 Westview Dr, Atlanta, GA 30310, USA.

|February 13, 2025

Summary

Melanoma Antigen Gene A4 (MAGE A4) is a cancer testis antigen found in tumors but not normal cells. This review explores MAGE A4

Keywords:

MAGE-A4 adoptive T cell therapy antibody cancer testis antigen esophageal cancer immunotherapy ovarian cancer sarcoma solid tumors

More Related Videos

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Related Experiment Videos

Last Updated: May 28, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Area of Science:

Oncology
Immunology
Genetics

Background:

Melanoma Antigen Gene A4 (MAGE A4) is a cancer testis antigen (CTA).
MAGE A4 is normally expressed in germline cells but absent in somatic cells.
MAGE A4 is expressed in various cancers, including synovial sarcoma, ovarian cancer, and non-small cell lung cancer.

Purpose of the Study:

To review MAGE A4's function and expression patterns.
To summarize current clinical trials targeting MAGE A4 with immunotherapy.
To discuss challenges and opportunities in MAGE A4-targeted therapeutics.

Main Methods:

Literature review of scientific publications and clinical trial data.
Analysis of MAGE A4 expression profiles in different tumor types.
Evaluation of immunotherapeutic strategies targeting MAGE A4.

Main Results:

MAGE A4's restricted expression makes it a promising target for cancer immunotherapy.
Several clinical trials are investigating MAGE A4-targeted therapies.
Understanding MAGE A4's role is crucial for developing effective treatments.

Conclusions:

MAGE A4 represents a significant target for developing novel cancer immunotherapies.
Further research and clinical trials are needed to overcome therapeutic challenges.
Targeted MAGE A4 therapies hold potential for treating specific malignancies.